Long-term study of seralutinib for pulmonary arterial hypertension
Part of Lungs & breathing clinical trials.
This trial is for people with pulmonary arterial hypertension (PAH) who have already completed a previous study of the drug seralutinib. It offers continued access to the treatment so doctors can watch its safety and effects over a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished a prior study of seralutinib for PAH.
- You must be willing to follow the study schedule and procedures.
- Women who could become pregnant must have a negative pregnancy test and use effective birth control during the study and for 30 days after.
- Men who are not sterilized and are sexually active with a woman who could become pregnant must use a condom during the study and for 90 days after.
- You should not have any serious medical condition that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called sotatercept for people with pulmonary arterial hypertension (PAH), a condition where the blood vessels in the lungs are narrow, making the heart work harder. The goal is to see if this medicine can help improve symptoms and daily function.
This study tests whether people with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs, can safely stop taking the medication sotatercept after being on it for at least 6 months and doing well. It aims to see if those who stop can maintain their health without the drug.
This study provides continued access to an investigational inhaled medicine (treprostinil palmitil inhalation powder) for people with pulmonary arterial hypertension (PAH) or pulmonary hypertension linked to interstitial lung disease (PH-ILD) who have already been in earlier studies of this treatment. It allows you to keep receiving the treatment under medical supervision.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. The study aims to see if the drug can improve symptoms and exercise ability.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
This study follows people with pulmonary arterial hypertension (PAH) to see how safe and effective ralinepag is over the long term. It may help your care team understand what to expect from continued treatment and monitoring.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.